Departments of Pathology and Preventive Medicine, Northwestern University Feinberg School of Medicine and Robert H. Lurie Cancer Center, Chicago, Illinois, USA.
Clin Cancer Res. 2009 Nov 15;15(22):6800-9. doi: 10.1158/1078-0432.CCR-09-0312. Epub 2009 Nov 10.
Recent studies suggest that children <24 months with stage I favorable histology Wilms tumors <550 g [very low risk Wilms tumors (VLRWT)] have an excellent prognosis when treated with nephrectomy only, without adjuvant chemotherapy. The identification of risk categories within VLRWT may enable refinement of their definition and optimization of their therapy.
To define biologically distinct subsets, global gene expression analysis was done on 39 VLRWT that passed all quality-control parameters and the clusters identified were validated in an independent set of 11 VLRWT. Validation of select differentially expressed genes was done with immunohistochemistry on a tissue microarray from 20 of 39 tumors. Loss of heterozygosity (LOH) for 11p15, 1p, and 16q was analyzed in 52 tumors using PCR.
Two distinctive clusters were identified. One cluster included 9 tumors with epithelial differentiated tubular histology, paucity of nephrogenic rests, lack of LOH for 1p, 16q, and 11p, absence of relapse, and a unique gene expression profile consistent with arrest following mesenchymal-to-epithelial transition. The second cluster included 13 tumors with mixed histology, intralobar nephrogenic rests, and decreased expression of WT1. Three of 6 relapses occurred in this cluster. Of 43 informative tumors, 11p LOH was present in 5 of 5 relapses and 11 of 38 nonrelapses.
Two subsets comprising a total of 56% of VLRWT are identified that have pathogenetic and molecular differences and apparent differences in risk for relapse. If these predictors can be prospectively validated, this would enable the refinement of clinical stratification and less arbitrary definition of VLRWT.
最近的研究表明,对于 24 个月以下、肿瘤组织学 I 期且瘤重<550g(极低危威尔姆斯瘤(VLRWT))的患儿,仅行肾切除术而不接受辅助化疗即可获得极佳的预后。VLRWT 中危险类别的确定可能有助于明确其定义,并优化其治疗方案。
为了确定具有生物学差异的亚群,对 39 例通过所有质量控制参数的 VLRWT 进行了全基因组基因表达分析,并在一组 11 例 VLRWT 中对鉴定出的聚类进行了验证。在 20 例肿瘤的组织微阵列上使用免疫组织化学法对选定的差异表达基因进行了验证。利用 PCR 分析了 52 例肿瘤中 11p15、1p 和 16q 的杂合性缺失(LOH)情况。
鉴定出两个截然不同的聚类。一个聚类包括 9 例具有上皮分化的管状组织学特征、肾胚细胞瘤稀少、1p、16q 和 11p 缺失 LOH、无复发以及与间充质向上皮转化后停滞相关的独特基因表达谱的肿瘤。第二个聚类包括 13 例具有混合组织学特征、叶内肾胚细胞瘤和 WT1 表达减少的肿瘤。6 例复发中有 3 例发生在该聚类中。在 43 例可评估的肿瘤中,11p LOH 存在于 5 例复发肿瘤和 11 例非复发肿瘤中。
确定了两种共占 VLRWT 总数 56%的亚群,它们具有发病机制和分子上的差异,以及复发风险的明显差异。如果这些预测指标能够前瞻性验证,将有助于完善临床分层,减少对 VLRWT 的任意定义。